Natasha Muench, auteur sur Digestive Cancers Europe - Page 3 of 3

EMA recommends approval for nivolumab (Opdivo) plus ipilimumab (Yervoy) as a first-line treatment for adults with advanced oesophageal squamous cell carcinoma (OSCC) with PD-L1 expression

EMA approves two combination-treatments for an aggressive oesophageal cancer

EMA recommends approval for nivolumab (Opdivo) plus ipilimumab (Yervoy) as a first-line treatment for adults with advanced oesophageal squamous cel...